As you can see, it's not an easy tightrope to walk consistently. Worse, you have to take time out at least once a month to get your blood checked (for PT/INR) to be sure you're on the right dose (and we then need to (re)adjust your warfarin dose according to your INR in order to help you reach your goal). What a pain (for both of us)! Not to mention the additional cost of lab testing . . .
Well, last year, the FDA approved the use of Pradaxa (dabigatran) , an oral anticoagulant (direct thrombin inhibitor), to reduce the risk for stroke in patients with atrial fibrillation. The upside? No need for periodic lab testing as there's only one dose! The downside? It's expensive! Worse, if you do bleed, there's no way to stop it and purposefully thicken your blood (at least we can do this if you're bleeding from too much warfarin).
This past week, the FDA approved the use of Xarelto (rivaroxaban) , another oral anticoagulant that works through a different pathway (factor Xa inhibitor) to prevent strokes in patients with atrial fibrillation. The upside? Again, no need for periodic lab testing as there's only one dose! The downside? It's expensive! And just like with Pradaxa, there's no way to stop the bleeding if you're so unlucky.
From no choice to an abundance of choices! But which drug do you choose? For most of us, that question will really be answered by our insurance company who will most likely base the decision upon overall cost, assuming similar efficacy. In the meantime, consider calculating your risk for stroke due to atrial fibrillation and then compare it your risk of bleeding out from warfarin . The former should exceed the latter if you're going to take some anticoagulant for the rest of your life. Then chat w/your family doc and discuss whether there's any benefit for you to consider one of these two newer options.